Source-based product analysis. This article contains no Vastkind hands-on test or original product measurements.
Disclosure: This review contains affiliate links. If you buy through them, Vastkind may earn a commission at no extra cost to you.
The most revealing part of a supplement trial can be the result its headline does not foreground. Some measurements may improve while the study's main comparison does not. Mitopure, Timeline's branded urolithin A, provides a useful example of how to read that situation without either dismissing the research or turning it into a promise to buyers.
This analysis examines one published randomized trial in detail and the current powder listing. It is not a systematic review of every urolithin A study or a test of the retail product.
First, identify the question the trial set out to answer
A 2022 randomized trial in JAMA Network Open assigned 66 adults aged 65–90 to urolithin A or placebo for four months. The study used 1,000 mg daily in softgels, not the 500 mg powder sachet discussed below; this is a trial description, not dosing advice. The primary-endpoint plan changed after the study began; the analysis plan was prepared before unblinding. The final primary outcomes were six-minute walking distance and maximum ATP production in hand muscle. Neither improved significantly relative to placebo.
Some secondary muscle-endurance measures improved at two months, and several plasma biomarker levels changed at four months. Adverse events did not differ significantly between groups. The study disclosed Amazentis funding and author employment, ownership, patent, and leadership interests involving the company.
The findings are mixed, and this adverse-event comparison does not establish universal or long-term safety.
Why “improved” needs a second half
When evaluating any trial, finish the sentence: improved what, compared with whom, over which period? Those details prevent several different questions from collapsing into one favorable adjective.
A primary outcome is designated to address a main study question. Secondary outcomes can reveal informative effects, but selecting only favorable ones after the results are available risks overstating the overall picture. A biomarker may help explain a mechanism without establishing a benefit that a person would notice in daily life.
Imagine a hypothetical study in which both groups improve at a walking test. Reporting only the supplemented group's improvement would leave out the comparison needed to interpret it. Conversely, a nonsignificant difference is not proof that the intervention can never work under any conditions. It means that particular analysis has not established the claimed difference.
A stronger assessment would combine prespecified outcomes across relevant trials, independent replication, and evidence that a measured effect matters outside the testing room. Those are the standards we would apply before endorsing a promised improvement in everyday life.
The ingredient and the sachet are separate questions
On Timeline's product comparison page, checked on 6 September 2026, the powder is listed as one sachet containing 500 mg of Mitopure, with raspberry flavor and no added sugar. Those are manufacturer descriptions, not our laboratory or sensory findings. Product labels and formulations can change; check the exact item offered in your market.
We have not measured what is in a sachet, assessed taste or mixing, or compared batch quality. Our earlier claims about texture, convenience, superior quality, and value were not supported by a documented Vastkind test and have been removed.
For a product analysis, the useful record would include the formulation and batch, ingredient quantities, relevant testing documentation, and a dated cost for the actual format. A clinical ingredient study cannot by itself answer whether a powder tastes good or whether its price is justified.
A practical filter for the sales page
Before accepting a scientific claim, ask:
- Does the linked paper study the stated ingredient and a relevant population?
- Is the advertised benefit a main outcome, another measurement, or an interpretation?
- Does the comparison support the wording, including any promised magnitude or timeline?
- Are funding and commercial interests visible?
Commercial involvement does not automatically invalidate a result. It belongs in the reader's assessment alongside the design, reporting, and replication record.
In the United States, FDA does not approve dietary supplements for safety and effectiveness before marketing. A supplement listing should not be read as equivalent to a medicine's approval for a particular treatment.
Mitopure remains an interesting case for following human evidence carefully. This article supplies that reading framework, without a buying score or an individual treatment recommendation. For a related distinction, see why a change in biological-age testing does not establish added lifespan.
Manufacturer offer (affiliate link): Mitopure product information.
Editorial correction, 6 September 2026: We clarified trial endpoints and commercial interests, removed undocumented taste and use claims, and withdrew unsupported quality and buying judgments. The original publication date and URL have been retained.
This is educational analysis, not individualized medical advice.
